Login
Home
Charts
Search
Watchlist
Products

Avience Biomedicals Ltd

AVIENCE·NSE
331.90+1.59%Tue, 22 Sept '26 09:30

Avience Biomedicals Ltd

AVIENCE
NSE
331.90
+1.59%
|Tue, 22 Sept '26 09:30
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
181Cr
Close
Close Price
330.00
Industry
Industry
Trading
PE
Price To Earnings
21.22
PS
Price To Sales
3.45
Revenue
Revenue
53Cr
Rev Gr TTM
Revenue Growth TTM
16.06%
PAT Gr TTM
PAT Growth TTM
23.28%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
21242726
Growth YoY
Revenue Growth YoY%
29.15.0
Expenses
ExpensesCr
16182018
Operating Profit
Operating ProfitCr
5778
OPM
OPM%
23.127.027.029.9
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
1111
Depreciation
DepreciationCr
0011
PBT
PBTCr
4677
Tax
TaxCr
1222
PAT
PATCr
3454
Growth YoY
PAT Growth YoY%
60.4-1.2
NPM
NPM%
13.617.416.916.4
EPS
EPS
0.00.00.00.0
QuarterSep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
21242726
Growth YoY
Revenue Growth YoY%
29.15.0
Expenses
ExpensesCr
16182018
Operating Profit
Operating ProfitCr
5778
OPM
OPM%
23.127.027.029.9
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
1111
Depreciation
DepreciationCr
0011
PBT
PBTCr
4677
Tax
TaxCr
1222
PAT
PATCr
3454
Growth YoY
PAT Growth YoY%
60.4-1.2
NPM
NPM%
13.617.416.916.4
EPS
EPS
0.00.00.00.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2024Mar 2025Mar 2026
Revenue
RevenueCr
244553
Growth
Revenue Growth%
88.816.1
Expenses
ExpensesCr
203438
Operating Profit
Operating ProfitCr
41115
OPM
OPM%
17.325.428.4
Other Income
Other IncomeCr
010
Interest Expense
Interest ExpenseCr
112
Depreciation
DepreciationCr
111
PBT
PBTCr
31012
Tax
TaxCr
134
PAT
PATCr
279
Growth
PAT Growth%
228.923.3
NPM
NPM%
9.015.716.7
EPS
EPS
6.618.721.7
Financial YearMar 2024Mar 2025Mar 2026
Revenue
RevenueCr
244553
Growth
Revenue Growth%
88.816.1
Expenses
ExpensesCr
203438
Operating Profit
Operating ProfitCr
41115
OPM
OPM%
17.325.428.4
Other Income
Other IncomeCr
010
Interest Expense
Interest ExpenseCr
112
Depreciation
DepreciationCr
111
PBT
PBTCr
31012
Tax
TaxCr
134
PAT
PATCr
279
Growth
PAT Growth%
228.923.3
NPM
NPM%
9.015.716.7
EPS
EPS
6.618.721.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
344
Reserves
ReservesCr
31927
Current Liabilities
Current LiabilitiesCr
212430
Non Current Liabilities
Non Current LiabilitiesCr
81014
Total Liabilities
Total LiabilitiesCr
355675
Current Assets
Current AssetsCr
233743
Non Current Assets
Non Current AssetsCr
121931
Total Assets
Total AssetsCr
355675
Financial YearMar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
344
Reserves
ReservesCr
31927
Current Liabilities
Current LiabilitiesCr
212430
Non Current Liabilities
Non Current LiabilitiesCr
81014
Total Liabilities
Total LiabilitiesCr
355675
Current Assets
Current AssetsCr
233743
Non Current Assets
Non Current AssetsCr
121931
Total Assets
Total AssetsCr
355675

Cash Flow

Consolidated
Standalone
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
136
Investing Cash Flow
Investing Cash FlowCr
-4-10-13
Financing Cash Flow
Financing Cash FlowCr
3105
Net Cash Flow
Net Cash FlowCr
04-2
Free Cash Flow
Free Cash FlowCr
-3-6-7
CFO To PAT
CFO To PAT%
47.147.867.5
CFO To EBITDA
CFO To EBITDA%
24.529.639.5
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
136
Investing Cash Flow
Investing Cash FlowCr
-4-10-13
Financing Cash Flow
Financing Cash FlowCr
3105
Net Cash Flow
Net Cash FlowCr
04-2
Free Cash Flow
Free Cash FlowCr
-3-6-7
CFO To PAT
CFO To PAT%
47.147.867.5
CFO To EBITDA
CFO To EBITDA%
24.529.639.5

Ratios

Consolidated
Standalone
Financial YearMar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
181
Price To Earnings
Price To Earnings
21.2
Price To Sales
Price To Sales
3.5
Price To Book
Price To Book
2.0
EV To EBITDA
EV To EBITDA
14.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
34.339.744.644.6
OPM
OPM%
17.325.428.428.4
NPM
NPM%
9.015.716.716.7
ROCE
ROCE%
18.425.023.223.2
ROE
ROE%
34.731.327.927.9
ROA
ROA%
6.212.611.711.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
181
Price To Earnings
Price To Earnings
21.2
Price To Sales
Price To Sales
3.5
Price To Book
Price To Book
2.0
EV To EBITDA
EV To EBITDA
14.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
34.339.744.644.6
OPM
OPM%
17.325.428.428.4
NPM
NPM%
9.015.716.716.7
ROCE
ROCE%
18.425.023.223.2
ROE
ROE%
34.731.327.927.9
ROA
ROA%
6.212.611.711.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Avience Biomedicals Ltd

  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/as-1cfc6485c5a4537c91cf71ab.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/lxwzl0zhxcsdo6g27gem8kfz.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/klp2qita5dkia4lnokzbu4c9.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/4u651rbaadfbstx0now4m4sj.pdf

Concall Transcript Summaries — Avience Biomedicals Ltd

  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AAVIENCE/transcript-notes/202603/as-1cfc6485c5a4537c91cf71ab.pdf